A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
AbbVie
OHSU Knight Cancer Institute
Eastern Cooperative Oncology Group
Dana-Farber Cancer Institute